Koninklijke Philips

Koninklijke Philips

Founded in 1891 by Gerard Philips and his father Frederik in Eindhoven, Koninklijke Philips began as a carbon-filament lamp factory and grew into one of Europe's largest electronics conglomerates. The firm shed its final consumer electronics divisions over the past two decades, culminating in the 2021 sale of its domestic appliances business to Hillhouse Capital, and now operates exclusively as a health-technology company focused on diagnosis, treatment, and home care. Philips structures its investment and business activity around four reporting segments: Diagnosis & Treatment, Connected Care, Personal Health, and a smaller segment labeled Other. The Diagnosis & Treatment unit includes imaging systems, ultrasound, and image-guided therapy devices — areas where Philips competes directly with Siemens Healthineers and GE HealthCare. Connected Care covers patient monitoring, hospital enterprise informatics, and sleep and respiratory care, a category that generated significant legal attention following a large-scale recall of certain ventilators and CPAP devices starting in 2021. Personal Health includes oral healthcare, mother and child care, and male grooming products. The firm maintains research and manufacturing facilities across the Netherlands, the United States, and China, and reported €18.2 billion in group sales for the full year 2023 (per the firm's annual report, 2024). Headquartered in Amsterdam, Philips employed roughly 69,700 people globally as of year-end 2023. The company's legal structure anchors around Koninklijke Philips N.V., a publicly traded entity listed on Euronext Amsterdam and the New York Stock Exchange. Roy Jakobs assumed the role of President and CEO in October 2022, succeeding Frans van Houten after a decade-long tenure that oversaw the health-tech pivot. Jakobs previously led the Connected Care business and took the helm during an intense period of regulatory scrutiny and legal settlement negotiations related to the respiratory-device recall. In April 2024, Philips reached a consent decree with the U.S. Department of Justice and the FDA, finalizing the terms under which it would continue remediation efforts and face temporary restrictions on new respiratory-device sales in the U.S. (per the firm, April 2024). Philips differs structurally from most entities Altss tracks because it is a publicly traded operating company, not a family office or private investment partnership. Its governance resembles a European multinational with a two-tier board structure and a supervisory board that includes former leaders from Unilever, Royal DSM, and SAP. The firm does not manage external capital as an asset manager, but its internal R&D pipeline and M&A program — recent years have included acquisitions of BioTelemetry, Capsule Technologies, and Vesper Medical — function as a concentrated deployment organization within a single corporate mandate. The absence of family control or wealth-origin concentration separates Philips fundamentally from the SFO/MFO universe, making its profile relevant chiefly as a comparative benchmark for allocators evaluating direct corporate healthcare exposure.